drugset / Trial / NCT00327197

Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

NCT00327197

Phase 1 Terminated 47 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects. To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.

Timeline

Start
2005-08-02
Primary completion
2011-06-06
Completion
2011-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified 0.5 mg/kg Oral

Indications